Methyltransferases Market Size, Share, Growth, and Industry Analysis, By Types (Histone Methyltransferases, N-terminal Methyltransferases, DNA/RNA Methyltransferases, Others, ), By Applications (Drug Discovery and Development, Cancer Treatment, Others, ) , and Regional Insights and Forecast to 2035

Methyltransferases Market Size

The Global Methyltransferases Market size was USD 370.14 Million in 2025 and is projected to reach USD 389.94 Million in 2026, USD 410.8 Million in 2027, and USD 623.32 Million by 2035, exhibiting a CAGR of 5.35% during the forecast period [2026-2035]. The market is expanding due to rising demand for epigenetics research, cancer diagnostics, and precision medicine solutions. More than 68% of biotechnology companies are increasing investment in genomic testing and enzyme-based molecular analysis. Around 61% of pharmaceutical research programs are now using methyltransferase-related technologies for drug development and targeted therapy studies.

The US Methyltransferases Market is witnessing stable growth due to strong pharmaceutical research infrastructure and increasing focus on molecular diagnostics. Nearly 72% of biotechnology laboratories in the country are conducting epigenetic studies involving DNA and RNA methylation analysis. Around 66% of oncology research programs are using methyltransferase technologies for cancer biomarker identification and targeted treatment development. In addition, approximately 58% of clinical research organizations are adopting automated genomic testing systems to improve testing efficiency and reduce laboratory processing time. Growing investment in personalized medicine and advanced sequencing technologies continues to support market demand across healthcare and life science sectors.

Key Findings

• Market Size: Global Methyltransferases Market reached USD 370.14 Million in 2025, USD 389.94 Million in 2026, and USD 623.32 Million by 2035 with 5.35% CAGR.
• Growth Drivers: Around 68% biotechnology firms and 61% pharmaceutical laboratories increased methylation research activities supporting advanced diagnostics and precision treatment demand.
• Trends: Nearly 59% genomic laboratories adopted automated methylation testing systems while 54% healthcare providers expanded personalized medicine research programs globally.
• Key Players: Bio-Techne, Abcam, New England Biolabs, Cell Signaling Technology, OriGene Technologies & more.
• Regional Insights: North America held 38% market share, Europe 29%, Asia-Pacific 24%, and Middle East & Africa 9% due to expanding biotechnology research activities.
• Challenges: Nearly 48% laboratories face technical workflow complexity, while 42% biotechnology firms report skilled workforce shortages affecting methyltransferase research operations globally.
• Industry Impact: Around 63% oncology programs and 57% genomic studies increased methyltransferase usage for biomarker testing and targeted therapeutic research activities.
• Recent Developments: Nearly 46% manufacturers introduced advanced assay kits, while 39% companies expanded enzyme testing solutions for genomic and molecular diagnostics.

The Methyltransferases Market is becoming an important part of modern biotechnology and pharmaceutical research because of its growing role in epigenetics and molecular diagnostics. Nearly 64% of precision medicine programs now include methylation analysis for disease detection and treatment planning. Around 52% of healthcare research centers are focusing on RNA modification and gene regulation studies involving methyltransferases. The market is also witnessing increasing demand for automated sequencing systems, with approximately 49% of genomic laboratories upgrading molecular testing infrastructure to improve research speed and testing accuracy across clinical and academic applications.

Methyltransferases Market Trends

The Methyltransferases Market is showing strong expansion due to the growing use of epigenetics research, cancer studies, and advanced drug discovery programs across biotechnology and pharmaceutical sectors. More than 68% of research laboratories are now focusing on enzyme-based molecular analysis, which has increased the demand for methyltransferases in genomic and proteomic applications. Around 57% of biotechnology firms are investing in DNA methylation studies to improve targeted therapy development. In clinical research activities, nearly 61% of ongoing epigenetic testing projects include methyltransferase-related analysis for disease identification and biomarker studies.

Technological improvements in sequencing systems and molecular diagnostics are further supporting the Methyltransferases Market growth. About 58% of genomic testing centers have shifted toward automated methylation analysis platforms to reduce manual errors and improve workflow efficiency. In addition, nearly 46% of research collaborations between pharmaceutical companies and academic institutions are focused on enzyme engineering and methyltransferase innovation. Growing awareness regarding early disease detection and the increasing use of epigenetic biomarkers continue to create strong demand across global healthcare and research sectors.

Methyltransferases Market Dynamics

OPPORTUNITY

"Expansion of Precision Medicine and Epigenetic Research"

The growing focus on precision medicine is creating major opportunities for the Methyltransferases Market. Nearly 66% of healthcare research organizations are increasing investment in personalized therapies based on genetic and epigenetic profiling. Around 59% of oncology studies now use methylation biomarkers for identifying cancer progression and treatment response patterns. In addition, over 52% of pharmaceutical development programs are integrating methyltransferase analysis into drug screening activities. Research institutions are also expanding enzyme-based molecular studies, with approximately 64% of genome-related projects involving DNA and RNA methylation analysis. The increasing demand for targeted treatment methods and biomarker discovery is expected to strengthen the use of methyltransferases in diagnostics, therapeutic development, and advanced clinical applications across multiple healthcare sectors.

DRIVERS

"Rising Demand for Cancer and Genetic Research"

The rapid increase in cancer and genetic disorder research is a key driver for the Methyltransferases Market. More than 71% of biotechnology laboratories are focusing on epigenetic mechanisms to improve disease understanding and treatment development. Nearly 62% of cancer diagnostic studies involve methylation testing for tumor detection and biomarker identification. Pharmaceutical companies are also increasing enzyme-related research activities, with around 56% of drug discovery programs using methyltransferases for molecular analysis. In the academic sector, approximately 67% of molecular biology departments are conducting research linked to DNA methylation and gene regulation. The increasing use of next-generation sequencing and advanced diagnostic platforms is further supporting the market demand for methyltransferases in both clinical and research applications.

RESTRAINTS

"High Complexity in Enzyme-Based Research Procedures"

The Methyltransferases Market faces restraints due to the complex nature of enzyme-related research and laboratory workflows. Nearly 48% of small research facilities face operational challenges because of the advanced technical expertise required for methyltransferase analysis. Around 44% of laboratories report difficulties in maintaining enzyme stability and reaction accuracy during experimental procedures. In addition, approximately 39% of clinical testing centers experience limitations in handling high-throughput methylation studies due to complicated sample preparation processes. The shortage of trained professionals in molecular diagnostics and epigenetic analysis also impacts market growth, with over 42% of biotechnology companies reporting skill gaps in advanced genomic research activities.

CHALLENGE

"Rising Costs and Limited Standardization in Research Applications"

One of the major challenges in the Methyltransferases Market is the increasing operational cost associated with advanced genomic and epigenetic studies. Around 53% of research organizations report higher spending on sequencing technologies, enzyme purification systems, and specialized laboratory equipment. Nearly 47% of biotechnology firms face issues related to inconsistent testing standards across research facilities, affecting result accuracy and reproducibility. In addition, about 41% of clinical laboratories experience delays in regulatory approval processes due to the lack of unified protocols for methylation analysis. The market also faces data interpretation challenges, as more than 38% of researchers report difficulties in analyzing complex epigenetic datasets generated from large-scale molecular studies.

Segmentation Analysis

The Methyltransferases Market is divided by type and application, with strong demand coming from biotechnology laboratories, pharmaceutical companies, and research institutes. The Global Methyltransferases Market size was USD 370.14 Million in 2025 and is projected to touch USD 389.94 Million in 2026 to USD 623.32 Million by 2035, exhibiting a CAGR of 5.35 % during the forecast period [2025-2035]. Increasing focus on epigenetics, molecular diagnostics, and targeted therapy development is supporting market expansion. More than 64% of genomic research projects now use methyltransferase-related analysis for DNA and RNA studies. Around 58% of pharmaceutical research facilities are integrating enzyme-based testing into drug development programs. Demand for advanced sequencing methods and precision medicine solutions continues to support the growth of different market segments across healthcare and life science industries.

By Type

Histone Methyltransferases

Histone methyltransferases hold a significant share in the Methyltransferases Market due to their increasing use in chromatin research and cancer-related studies. Nearly 61% of epigenetic research laboratories are using histone methyltransferases for gene expression analysis and biomarker discovery. Around 56% of oncology-focused projects include histone modification studies for better disease understanding. Growing use of targeted therapies and advanced sequencing technologies is also increasing segment demand across pharmaceutical and biotechnology sectors.

Histone Methyltransferases held the largest share in the Methyltransferases Market, accounting for USD 122.14 Million in 2025, representing 33% of the total market. This segment is expected to grow at a CAGR of 5.8% from 2025 to 2035, driven by increasing cancer research, epigenetic studies, and precision medicine development.

N-terminal Methyltransferases

N-terminal methyltransferases are gaining attention because of their role in protein regulation and cellular function analysis. Nearly 47% of proteomics research centers are using these enzymes for studying protein interactions and molecular signaling activities. Around 42% of biotechnology companies are investing in advanced protein engineering studies involving N-terminal methyltransferases. The growing demand for protein-based therapeutics and enzyme research is supporting the expansion of this segment.

N-terminal Methyltransferases accounted for USD 74.02 Million in 2025, representing 20% of the total market share. This segment is projected to grow at a CAGR of 4.9% from 2025 to 2035 due to increasing use in protein analysis, molecular biology, and biotechnology research activities.

DNA/RNA Methyltransferases

DNA/RNA methyltransferases are widely used in genetic testing, molecular diagnostics, and RNA modification studies. More than 68% of genomic sequencing laboratories rely on DNA/RNA methyltransferases for methylation analysis and disease detection procedures. Around 63% of clinical research projects involving genetic disorders include RNA methylation studies. Rising demand for personalized medicine and advanced diagnostic technologies is further supporting this segment growth.

DNA/RNA Methyltransferases accounted for USD 133.25 Million in 2025, holding 36% of the total market share. This segment is anticipated to expand at a CAGR of 5.9% during the forecast period due to increasing adoption in genomic testing, disease diagnostics, and therapeutic research programs.

Others

The others segment includes specialized methyltransferases used in industrial biotechnology, academic research, and experimental molecular studies. Nearly 38% of research institutes are exploring new enzyme applications related to synthetic biology and metabolic engineering. Around 35% of laboratory development programs involve customized enzyme solutions for niche research areas. The increasing need for innovation in enzyme technologies continues to support this segment.

Others accounted for USD 40.73 Million in 2025, representing 11% of the total market. This segment is expected to grow at a CAGR of 4.5% from 2025 to 2035 due to increasing experimental research activities and emerging biotechnology applications.

By Application

Drug Discovery and Development

Drug discovery and development is one of the major application areas in the Methyltransferases Market. More than 67% of pharmaceutical companies are using methyltransferase-based studies for identifying new therapeutic targets and improving drug screening efficiency. Around 59% of enzyme-related clinical programs involve epigenetic testing for targeted therapy development. Increasing demand for precision medicine and advanced molecular analysis tools continues to strengthen this application segment across global pharmaceutical industries.

Drug Discovery and Development held the largest share in the market, accounting for USD 177.67 Million in 2025, representing 48% of the total market. This application segment is projected to grow at a CAGR of 5.7% from 2025 to 2035, supported by rising pharmaceutical research and increasing focus on targeted therapies.

Cancer Treatment

Cancer treatment applications are growing rapidly because methyltransferases are widely used in tumor profiling and biomarker analysis. Nearly 62% of oncology research institutes are focusing on methylation-based testing to improve cancer diagnosis and therapy selection. Around 57% of precision oncology studies involve enzyme-related molecular analysis for identifying treatment response patterns. Growing awareness regarding early cancer detection is further increasing the demand for this segment.

Cancer Treatment accounted for USD 125.85 Million in 2025, representing 34% of the total market share. This segment is expected to grow at a CAGR of 5.6% during the forecast period due to rising adoption of epigenetic therapies and molecular diagnostic technologies.

Others

The others application segment includes academic research, agricultural biotechnology, and industrial enzyme studies. Approximately 41% of university-based molecular biology projects are using methyltransferases for experimental gene regulation studies. Around 36% of biotechnology innovation programs are exploring enzyme applications in microbial and agricultural research. Increasing scientific interest in advanced molecular mechanisms is supporting demand for this segment.

Others accounted for USD 66.62 Million in 2025, holding 18% of the total market share. This segment is projected to expand at a CAGR of 4.6% from 2025 to 2035 due to increasing academic research and biotechnology innovation activities.

Methyltransferases Market Regional Outlook

The Methyltransferases Market is expanding across major regions due to rising investment in biotechnology, pharmaceutical research, and genomic testing. The Global Methyltransferases Market size was USD 370.14 Million in 2025 and is projected to touch USD 389.94 Million in 2026 to USD 623.32 Million by 2035, exhibiting a CAGR of 5.35 % during the forecast period [2026-2035]. North America accounts for 38% market share, Europe holds 29%, Asia-Pacific represents 24%, and Middle East & Africa contributes 9% share. Increasing demand for epigenetics research, cancer diagnostics, and personalized medicine is driving regional market development. Growth in healthcare infrastructure and laboratory automation is also supporting market expansion in both developed and emerging economies.

North America

North America holds a strong position in the Methyltransferases Market due to high investment in pharmaceutical research, genomic testing, and precision medicine programs. Nearly 69% of biotechnology companies in the region are involved in epigenetic research activities related to cancer and genetic disorders. Around 64% of molecular diagnostic laboratories are using methyltransferase-based testing methods for biomarker discovery and disease analysis. The presence of advanced healthcare infrastructure and strong research funding is supporting regional market growth. Academic research centers are also increasing enzyme-based studies, with approximately 58% of genomic projects involving DNA methylation analysis and targeted therapy development.

North America held the largest share in the Methyltransferases Market, accounting for USD 148.18 Million in 2026, representing 38% of the total market. This region is expected to grow at a CAGR of 5.6% from 2026 to 2035, driven by increasing biotechnology investments, advanced genomic research, and rising demand for precision medicine solutions.

Europe

Europe is witnessing stable growth in the Methyltransferases Market because of increasing research activities in molecular biology and pharmaceutical development. More than 61% of research institutes across the region are conducting studies related to epigenetics and enzyme-based diagnostics. Around 55% of pharmaceutical companies are focusing on targeted drug development programs involving methyltransferase technologies. Government support for life science innovation and increasing collaboration between academic institutions and biotechnology firms are further supporting market demand. In addition, nearly 49% of oncology research projects in Europe involve methylation-based biomarker testing for cancer diagnosis and treatment analysis.

Europe accounted for USD 113.08 Million in 2026, representing 29% of the global market share. The region is projected to grow at a CAGR of 5.2% during the forecast period due to rising pharmaceutical research, growing healthcare investments, and expanding genomic testing activities.

Asia-Pacific

Asia-Pacific is becoming an important region in the Methyltransferases Market due to rapid growth in biotechnology infrastructure and healthcare research activities. Nearly 66% of pharmaceutical manufacturing companies in the region are investing in molecular diagnostics and enzyme-based drug development programs. Around 59% of genomic testing laboratories are adopting advanced sequencing technologies involving methyltransferase analysis. Increasing healthcare spending and rising awareness regarding early disease detection are supporting market expansion. Academic and government research organizations are also increasing investment in precision medicine, with approximately 53% of research collaborations focusing on genetic and epigenetic studies.

Asia-Pacific accounted for USD 93.59 Million in 2026, holding 24% of the total market share. This region is expected to grow at a CAGR of 5.8% from 2026 to 2035 due to expanding biotechnology industries, improving healthcare infrastructure, and increasing demand for genomic research applications.

Middle East & Africa

Middle East & Africa is gradually expanding in the Methyltransferases Market with increasing investment in healthcare modernization and biotechnology research. Around 46% of research laboratories in the region are improving molecular testing capabilities for disease diagnosis and genomic analysis. Nearly 41% of pharmaceutical and clinical research facilities are adopting enzyme-based technologies for cancer and genetic disorder studies. Government healthcare initiatives and growing partnerships with international biotechnology firms are helping regional market development. In addition, approximately 37% of healthcare institutions are increasing focus on personalized medicine and advanced laboratory diagnostics to improve treatment quality and disease management.

Middle East & Africa accounted for USD 35.09 Million in 2026, representing 9% of the total market share. This region is projected to grow at a CAGR of 4.8% during the forecast period due to increasing healthcare investments, rising genomic research activities, and improving diagnostic infrastructure.

List of Key Methyltransferases Market Companies Profiled

Investment Analysis and Opportunities in Methyltransferases Market

The Methyltransferases Market is attracting strong investment from biotechnology companies, pharmaceutical manufacturers, and research institutions due to rising demand for epigenetics and molecular diagnostics. Nearly 68% of pharmaceutical firms are increasing investment in enzyme-based research for targeted therapy development. Around 61% of biotechnology investors are focusing on genomic testing and methylation analysis technologies to improve disease detection and treatment precision. Academic research funding has also increased, with approximately 57% of life science institutions expanding laboratory capabilities for methyltransferase studies.

Growing demand for precision medicine is creating major investment opportunities across clinical diagnostics and cancer research. Nearly 63% of oncology-focused research programs are using methyltransferase analysis for biomarker identification and treatment monitoring. Around 54% of healthcare technology providers are investing in automated sequencing platforms and AI-supported molecular analysis systems. In addition, approximately 48% of biotechnology partnerships are focused on enzyme engineering and RNA modification studies. Expanding healthcare infrastructure in emerging economies and increasing research collaborations between pharmaceutical companies and universities are expected to support long-term market opportunities in the Methyltransferases Market.

New Products Development

New product development in the Methyltransferases Market is increasing rapidly due to advancements in genomic research, molecular diagnostics, and epigenetic testing technologies. Nearly 66% of biotechnology companies are developing advanced methyltransferase assay kits to improve testing speed and laboratory accuracy. Around 59% of research organizations are focusing on next-generation sequencing-compatible enzyme products for high-throughput genomic analysis. The growing use of automated diagnostic systems has also encouraged manufacturers to launch improved enzyme purification and detection solutions.

More than 53% of pharmaceutical companies are investing in RNA methylation tools and targeted therapy research products to support personalized medicine applications. Around 46% of product launches in the market are linked to cancer biomarker analysis and precision oncology research. Companies are also developing high-sensitivity enzyme reagents and multiplex testing systems to reduce experimental errors and improve workflow efficiency. In addition, approximately 42% of newly introduced methyltransferase products are designed for academic research institutes and biotechnology laboratories focusing on epigenetics and protein modification studies.

Developments

• Bio-Techne: Expanded its epigenetics research portfolio by introducing advanced methyltransferase assay solutions with nearly 32% higher testing efficiency and improved compatibility with automated genomic analysis systems used in biotechnology laboratories.
• Abcam: Increased production capacity for methyltransferase antibodies and research reagents after witnessing over 28% growth in demand from cancer research institutes and pharmaceutical development centers focusing on precision medicine.
• New England Biolabs: Launched improved enzyme reaction kits designed for high-throughput sequencing applications, helping laboratories reduce processing errors by approximately 24% during genomic testing procedures.
• Cell Signaling Technology: Developed new molecular analysis products focused on histone methylation studies, supporting nearly 36% faster biomarker detection in advanced oncology and epigenetics research programs.
• OriGene Technologies: Strengthened its biotechnology research product line with advanced RNA methylation solutions, improving laboratory workflow performance by almost 27% in molecular diagnostics and therapeutic research activities.

Report Coverage

The report on the Methyltransferases Market provides detailed analysis of market trends, growth factors, segmentation, regional outlook, competitive landscape, and future industry opportunities. It studies major market types including Histone Methyltransferases, N-terminal Methyltransferases, DNA/RNA Methyltransferases, and other specialized enzymes used in biotechnology and pharmaceutical research. The report also covers major application areas such as drug discovery and development, cancer treatment, and academic molecular research.

The SWOT analysis included in the report highlights major strengths, weaknesses, opportunities, and threats affecting the market. Around 69% of market strength comes from increasing demand for epigenetic research and precision medicine technologies. Strong adoption of genomic sequencing and molecular diagnostics is also supporting industry expansion. However, nearly 44% of research laboratories face technical challenges related to enzyme stability and testing complexity, which acts as a key weakness for the market.

Regional analysis in the report covers North America, Europe, Asia-Pacific, and Middle East & Africa, offering detailed information regarding market share, industry demand, and research developments. The report further includes company profiling, product development activities, investment analysis, and recent strategic developments influencing the Methyltransferases Market across global healthcare and biotechnology industries.

Future Scope

The future scope of the Methyltransferases Market remains strong due to rising demand for precision medicine, genomic sequencing, and epigenetic research across healthcare and biotechnology sectors. Nearly 71% of pharmaceutical companies are expected to increase focus on targeted therapy research involving methylation analysis and enzyme-based diagnostics. Around 65% of biotechnology laboratories are planning to adopt automated molecular testing systems for improving genomic workflow efficiency and reducing laboratory errors. The increasing use of AI-supported diagnostics and advanced sequencing technologies is expected to support long-term market growth.

Research activities related to cancer biomarkers and genetic disorders are likely to create new opportunities for methyltransferase applications. More than 62% of oncology research programs are expected to include DNA and RNA methylation analysis for early disease detection and personalized treatment planning. Around 58% of healthcare institutions are expanding investment in molecular diagnostics and precision oncology programs. Growing focus on RNA therapeutics and gene regulation studies is also expected to increase the use of methyltransferases in pharmaceutical development activities.

The market is also expected to witness increased innovation in enzyme purification systems, diagnostic assay kits, and biomarker identification technologies. Nearly 46% of product development programs are focusing on improving testing sensitivity and reducing analysis time in molecular diagnostics. The rising adoption of personalized healthcare solutions and increasing awareness regarding early disease detection will continue to support future opportunities in the Methyltransferases Market across global research and clinical industries.

Methyltransferases Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 370.14 Million in 2026
Market Size Value By	USD 623.32 Million by 2035
Growth Rate	CAGR of 5.35% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Histone Methyltransferases N-terminal Methyltransferases DNA/RNA Methyltransferases Others By Application : Drug Discovery and Development Cancer Treatment Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Methyltransferases Market expected to touch by 2035?

  The global Methyltransferases Market is expected to reach USD 623.32 Million by 2035.

• What CAGR is the Methyltransferases Market expected to exhibit by 2035?

  The Methyltransferases Market is expected to exhibit a CAGR of 5.35% by 2035.

• Who are the top players in the Methyltransferases Market?

  R&D Systems, Novus Biologicals, Abbexa, OriGene Technologies, Abcam, Abnova, IBL- America, Biorbyt, RayBiotech, New England Biolabs, Yeasen Biotechnology, Creative BioMart, Sigma-Aldrich, Epitherapeutics APS, Eisai, Sirtris, Cellcentric, Constellation Pharmaceuticals, Sequenom, Domainex, Bio-Techne, Cell Signaling Technology, LifeSpan BioSciences, BioVision,

• What was the value of the Methyltransferases Market in 2025?

  In 2025, the Methyltransferases Market value stood at USD 370.14 Million.

Related Reports

Pre-owned Healthcare Market Small Cell Lung Cancer Therapeutics Market Next-Generation Sequencing (NGS) Market Vegetable (HPMC) Capsule Market Non-opioid Pain Patches Market Disposable Medical Sensors Market